Chittasupho et al. developed CXCR4-targeted nanoparticles to enhance doxorubicin delivery to lung cancer cells, finding that CXCR4-specific nanocarriers improved drug accumulation and therapeutic efficacy, demonstrating that CXCR4 inhibition could be used in nanotechnology-driven chemotherapy enhancements (Chittasupho et al., 2014). Here, CXCR4 is linked to lung cancer.